Ansaripour's thesis explains how a middle-income country (in this case, focusing on Iran) can improve its drug reimbursement decision-making system.
- Doctoral student
- Promotor
- Co-promotor
- Datum
- vrijdag 6 jul 2018, 13:30 - 15:30
- Type
- Promotie
- Ruimte
- Senaatszaal
- Gebouw
- Erasmus Gebouw
- Locatie
- Campus Woudestein
Subsequently, his thesis is focused on use of a monoclonal antibody in breast cancer. Trastuzumab, an expensive drug, is widely used in the treatment of overexpressed human epidermal growth factor receptor 2 (HER2-positive) breast cancer and it has continued to be a topic of conversation in many healthcare systems since its launch into the pharmaceutical markets.
Three parts of important information are prepared in this thesis. Firstly, the current situation and subsequent consequences of the drug reimbursement decision-making system have been discussed in Iran. Secondly, some solutions are provided to improve limited health economics-related evidence in Iran. And finally, some recommendations are proposed to improve the system such as development a country-specific guideline for economic evaluations, development an independent pricing system, Improvement of post-marketing observations, and correcting former decisions.
